Loading...
Indian Pharmaceutical Exporter · #4 for Ceftriaxone · $9.2M export value · DGFT Verified
Aurobindo Pharma Ltd is the #4 Indian exporter of Ceftriaxone with $9.2M in export value and 184 verified shipments. Aurobindo Pharma Ltd holds a 3.2% market share in Ceftriaxone exports across 6 countries.
| 4 |
| 0.4% |
| TANZANIA | $19.3K | 1 | 0.2% |
| KENYA | $10.5K | 2 | 0.1% |
Aurobindo Pharma Ltd exports Ceftriaxone to 7 countries. The largest destination is MEXICO accounting for 61.1% of Aurobindo Pharma Ltd's Ceftriaxone shipments, followed by BRAZIL (36.6%) and NIGERIA (1.0%). These destinations reflect Aurobindo Pharma Ltd's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| AUROVIDA FARMACEUTICA, SA DE CV, | MEXICO | $4.4M | 94 |
| EUGIA PHARMA INDUSTRIA FARMACEUTICA | BRAZIL | $1.6M | 53 |
| BRAINFARMA INDUSTRIA QUIMICA E FARM | BRAZIL | $1.3M | 26 |
| AUROVIDA FARMACEUTICA, S.A, | MEXICO | $345.0K | 7 |
| AUROVIDA FARMACEUTICA S A | MEXICO | $270.9K | 6 |
| AUROVIDA FARMACEUTICA SA DE CV | MEXICO | $172.3K | 6 |
| AUROBINDO PHARMA INDUSTRIA FARMACEU | BRAZIL | $147.9K | 5 |
| PHILLIPS PHARMACEUTICALS (NIGERIA) | NIGERIA | $82.4K | 2 |
| AUROVIDA FARMACEUTICA, | MEXICO | $50.0K | 1 |
| EUGIA PHARMA INDUSTRIA FARMACEUTICA LIMITADA EUGIA PHARMA INDUSTRIA FARMACEUTICA LIMITED | BRAZIL | $50.0K | 1 |
Aurobindo Pharma Ltd supplies Ceftriaxone to 20 buyers globally. The largest buyer is AUROVIDA FARMACEUTICA, SA DE CV, (MEXICO), followed by EUGIA PHARMA INDUSTRIA FARMACEUTICA (BRAZIL) and BRAINFARMA INDUSTRIA QUIMICA E FARM (BRAZIL). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $98.3M worth of Ceftriaxone through 11,257 shipments from 850 suppliers to 162 countries, serving 2,555 buyers globally. Aurobindo Pharma Ltd contributes $9.2M to this total, accounting for 3.2% of India's Ceftriaxone exports. Aurobindo Pharma Ltd ships Ceftriaxone to 7 countries through 20 buyers.
Aurobindo Pharma Ltd's average Ceftriaxone shipment value is $50.0K per consignment, based on 184 shipments totaling $9.2M. The largest destination is MEXICO (61.1% of Aurobindo Pharma Ltd's Ceftriaxone exports).
Aurobindo Pharma Ltd ranks #4 among 850 Indian Ceftriaxone exporters with a 3.2% market share. The top 3 exporters are INNOVA CAPTAB LIMITED ($30.0M), AUROBINDO PHARMA LTD ($9.2M), CIPLA LIMITED ($6.7M). Aurobindo Pharma Ltd processed 184 shipments to 6 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CEFTRIAXONE FOR INJECTION 1G(AUROVIAX 10 | $4.8M | 101 |
| CEFTRIAXONE FOR INJECTION 1G(ceftriaxona | $1.2M | 25 |
| CEFTRIAXONE FOR INJECTION 1G(Ceftriaxone | $227.7K | 8 |
| CEFTRIAXONE FOR INJECTION 1G (CEFTRIAXONE FOR INJECTION USP 1G) (QTY-5665PAC)NOS | $99.6K | 3 |
| CEFTRIAXONE FOR INJECTION 1G (CEFTRIAXONE FOR INJECTION USP 1G) (QTY-5679 PAC) | $97.3K | 3 |
| CEFTRIAXONE FOR INJECTION 1G(CEFTRIAXONEFOR INJECTION USP 1G) (QTY-5015 PAC) | $86.8K | 3 |
| CEFTRIAXONE FOR INJECTION 1G(AUROXONE 10 | $82.4K | 2 |
| CEFTRIAXONE FOR INJECTION 1G (CEFTRIAXONE FOR INJECTION USP 1G) (QTY-4385 PAC)NOS | $76.1K | 3 |
| CEFTRIAXONE FOR INJECTION 1G (CEFTRIAXONE FOR INJECTION USP 1G) 50 (QTY- 4330 PAC)NOS | $75.3K | 3 |
| CEFTRIAXONE FOR INJECTION 1G (AUROVIAX 1 | $73.0K | 2 |
Aurobindo Pharma Ltd exports 61 distinct Ceftriaxone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CEFTRIAXONE FOR INJECTION 1G(AUROVIAX 10 with 101 shipments worth $4.8M.
What Aurobindo Pharma Ltd must comply with to export Ceftriaxone to its top destination countries
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Approval Process
Drug registration under NAFDAC guidelines. WHO-type CPP from India required.
Timeline: 6–18 months
GMP & Export Requirements
WHO GMP compliance; NAFDAC conducts overseas plant inspections
Certificate of Pharmaceutical Product (CPP) from CDSCO India; NAFDAC import permit
Note: India is the largest pharma supplier to Nigeria. NAFDAC has intensified Indian site inspections.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | INNOVA CAPTAB LIMITED | $30.0M | 600 | 20 | $50.0K |
| 4 | AUROBINDO PHARMA LTD ★ | $9.2M | 184 | 6 | $50.0K |
| 9 | CIPLA LIMITED | $6.7M | 266 | 5 | $25.0K |
| 10 | THEON PHARMACEUTICALS LIMITED | $6.3M | 503 | 14 | $12.6K |
Aurobindo Pharma Ltd ranks #4 among 850 Indian Ceftriaxone exporters. Average shipment value of $50.0K compared to the market average of $115.6K. The closest competitors by value are INNOVA CAPTAB LIMITED and CIPLA LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 1,199 | 10.7% |
| JNPT/ NHAVA SHEVA SEA | 819 | 7.3% |
| JNPT | 675 | 6.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 547 | 4.9% |
| DELHI AIR CARGO ACC (INDEL4) | 472 | 4.2% |
| MUNDRA SEA | 460 | 4.1% |
| DELHI AIR | 457 | 4.1% |
| SAHAR AIR | 451 | 4.0% |
Latest developments and market context
Detailed market intelligence for Ceftriaxone — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 162+ countries, 2,555+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Aurobindo Pharma Ltd's Ceftriaxone exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Aurobindo Pharma Ltd
Company Profile
0 products · $0 total trade · 0 categories
Access shipment-level records, pricing trends, and buyer contacts for Aurobindo Pharma Ltd.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ceftriaxone. For current shipment-level data, contact TransData Nexus.